AOD-9604 targets fat cells directly, promoting their breakdown, while MOTS-C improves overall metabolic function and insulin sensitivity
The strongest preclinical evidence supports BPC-157 use for tendon and ligament repair, gut-lining integrity in NSAID-related damage, and inflammation reduction in musculoskeletal tissues
The primary contraindication is a personal history of cancer, since its growth hormone-stimulating mechanism is not appropriate for patients with any oncological history
8,9 Patients typically complain of pain that starts with the first step on arising in the morning or after prolonged sitting
[7] [8] This activity detoxifies endogenous compounds such as peroxidised lipids and enables the breakdown of xenobiotics
The structural similarity of therapeutic peptides to endogenous biological molecules can provide better integration with natural physiological processes